New Key Statistics Module, Z-Score and F-Score
NAS:CBAY Key Ratios
| Market Cap $ M | 3,728.22 |
| Enterprise Value $ M | 3,448.46 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 12.65 |
| Price/Sales | 106.84 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 31.00 |
| EPS (TTM) $ | -0.99 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | 1.20 |
| 5-y EBITDA Growth Rate % | 7.80 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -39.90 |
| EV-to-EBITDA | -40.22 |
| PEG | -- |
| Shares Outstanding M | 114.79 |
| Net Margin (%) | -339.11 |
| Operating Margin % | -327.23 |
| Pre-tax Margin (%) | -339.11 |
| Quick Ratio | 10.96 |
| Current Ratio | 10.96 |
| ROA % (ttm) | -35.13 |
| ROE % (ttm) | -60.75 |
| ROIC % (ttm) | -423.81 |
| Dividend Yield % | -- |
| Altman Z-Score | 12.98 |
CBAY Number of Guru Trades
CBAY Volume of Guru Trades
Gurus Latest Trades with NAS:CBAY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:CBAY is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
CymaBay Therapeutics Inc Insider Transactions
No Available Data
News about NAS:CBAY
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers